FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100090684> ?p ?o ?g. }

• W2100090684 endingPage "940" @default.
• W2100090684 startingPage "934" @default.
• W2100090684 abstract "Objectives To test the hypothesis that early androgen deprivation therapy (ADT) has no proven survival advantage in older men with biochemical recurrence (BCR) of prostate cancer (PCa), and it may contribute to geriatric frailty. Methods We conducted a case-control study of men aged 60+ years with BCR on ADT (n = 63) vs PCa survivors without recurrence (n = 71). Frailty prevalence, “obese” frailty, Short Physical Performance Battery (SPPB) scores, and falls were compared. An exploratory analysis of frailty biomarkers (C-reactive protein, erythrocyte sedimentation rate, hemoglobin, albumin, and total cholesterol) was performed. Summary statistics and univariate and multivariate regression analyses were conducted. Results More patients on ADT were obese (body mass index >30; 46.2% vs 20.6%; P = .03). There were no statistical differences in SPPB (P = .41) or frailty (P = .20). Using a proposed “obese” frailty criteria, 8.7% in ADT group were frail and 56.5% were “prefrail,” compared with 2.9% and 48.8% of controls (P = .02). Falls in the last year were higher in the ADT group (14.3% vs 2.8%; P = .02). In analyses controlling for age, clinical characteristics, and comorbidities, the ADT group trended toward significance for “obese” frailty (P = .14) and falls (OR = 4.74, P = .11). Comorbidity significantly increased the likelihood of “obese” frailty (P = .01) and falls (OR 2.02, P = .01). Conclusions Men with BCR on ADT are frailer using proposed modified “obese” frailty criteria. They may have lower performance status and more falls. A larger, prospective trial is necessary to establish a causal link between ADT use and progression of frailty and disability. To test the hypothesis that early androgen deprivation therapy (ADT) has no proven survival advantage in older men with biochemical recurrence (BCR) of prostate cancer (PCa), and it may contribute to geriatric frailty. We conducted a case-control study of men aged 60+ years with BCR on ADT (n = 63) vs PCa survivors without recurrence (n = 71). Frailty prevalence, “obese” frailty, Short Physical Performance Battery (SPPB) scores, and falls were compared. An exploratory analysis of frailty biomarkers (C-reactive protein, erythrocyte sedimentation rate, hemoglobin, albumin, and total cholesterol) was performed. Summary statistics and univariate and multivariate regression analyses were conducted. More patients on ADT were obese (body mass index >30; 46.2% vs 20.6%; P = .03). There were no statistical differences in SPPB (P = .41) or frailty (P = .20). Using a proposed “obese” frailty criteria, 8.7% in ADT group were frail and 56.5% were “prefrail,” compared with 2.9% and 48.8% of controls (P = .02). Falls in the last year were higher in the ADT group (14.3% vs 2.8%; P = .02). In analyses controlling for age, clinical characteristics, and comorbidities, the ADT group trended toward significance for “obese” frailty (P = .14) and falls (OR = 4.74, P = .11). Comorbidity significantly increased the likelihood of “obese” frailty (P = .01) and falls (OR 2.02, P = .01). Men with BCR on ADT are frailer using proposed modified “obese” frailty criteria. They may have lower performance status and more falls. A larger, prospective trial is necessary to establish a causal link between ADT use and progression of frailty and disability." @default.
• W2100090684 created "2016-06-24" @default.
• W2100090684 creator A5012965788 @default.
• W2100090684 creator A5018605535 @default.
• W2100090684 creator A5038508194 @default.
• W2100090684 creator A5055581494 @default.
• W2100090684 creator A5077403751 @default.
• W2100090684 creator A5088131964 @default.
• W2100090684 date "2011-04-01" @default.
• W2100090684 modified "2023-10-03" @default.
• W2100090684 title "Obese Frailty, Physical Performance Deficits, and Falls in Older Men with Biochemical Recurrence of Prostate Cancer on Androgen Deprivation Therapy: A Case-control Study" @default.
• W2100090684 cites W1525217260 @default.
• W2100090684 cites W1530265335 @default.
• W2100090684 cites W1981430379 @default.
• W2100090684 cites W1997732940 @default.
• W2100090684 cites W1998049880 @default.
• W2100090684 cites W2003020102 @default.
• W2100090684 cites W2007110777 @default.
• W2100090684 cites W2011974825 @default.
• W2100090684 cites W2013136992 @default.
• W2100090684 cites W2016972400 @default.
• W2100090684 cites W2024785664 @default.
• W2100090684 cites W2041302513 @default.
• W2100090684 cites W2051903154 @default.
• W2100090684 cites W2062905962 @default.
• W2100090684 cites W2086554145 @default.
• W2100090684 cites W2089396531 @default.
• W2100090684 cites W2097692165 @default.
• W2100090684 cites W2110698392 @default.
• W2100090684 cites W2123499014 @default.
• W2100090684 cites W2127427656 @default.
• W2100090684 cites W2131692209 @default.
• W2100090684 cites W2151994499 @default.
• W2100090684 cites W2157487787 @default.
• W2100090684 cites W2158474094 @default.
• W2100090684 cites W2164059021 @default.
• W2100090684 cites W2316138036 @default.
• W2100090684 cites W4249663626 @default.
• W2100090684 doi "https://doi.org/10.1016/j.urology.2010.11.024" @default.
• W2100090684 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3074039" @default.
• W2100090684 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21269665" @default.
• W2100090684 hasPublicationYear "2011" @default.
• W2100090684 type Work @default.
• W2100090684 sameAs 2100090684 @default.
• W2100090684 citedByCount "56" @default.
• W2100090684 countsByYear W21000906842012 @default.
• W2100090684 countsByYear W21000906842013 @default.
• W2100090684 countsByYear W21000906842014 @default.
• W2100090684 countsByYear W21000906842015 @default.
• W2100090684 countsByYear W21000906842016 @default.
• W2100090684 countsByYear W21000906842017 @default.
• W2100090684 countsByYear W21000906842018 @default.
• W2100090684 countsByYear W21000906842019 @default.
• W2100090684 countsByYear W21000906842020 @default.
• W2100090684 countsByYear W21000906842021 @default.
• W2100090684 countsByYear W21000906842022 @default.
• W2100090684 countsByYear W21000906842023 @default.
• W2100090684 crossrefType "journal-article" @default.
• W2100090684 hasAuthorship W2100090684A5012965788 @default.
• W2100090684 hasAuthorship W2100090684A5018605535 @default.
• W2100090684 hasAuthorship W2100090684A5038508194 @default.
• W2100090684 hasAuthorship W2100090684A5055581494 @default.
• W2100090684 hasAuthorship W2100090684A5077403751 @default.
• W2100090684 hasAuthorship W2100090684A5088131964 @default.
• W2100090684 hasBestOaLocation W21000906842 @default.
• W2100090684 hasConcept C121608353 @default.
• W2100090684 hasConcept C126322002 @default.
• W2100090684 hasConcept C143998085 @default.
• W2100090684 hasConcept C2777008409 @default.
• W2100090684 hasConcept C2777899217 @default.
• W2100090684 hasConcept C2779159551 @default.
• W2100090684 hasConcept C2779466945 @default.
• W2100090684 hasConcept C2780192828 @default.
• W2100090684 hasConcept C2780221984 @default.
• W2100090684 hasConcept C38180746 @default.
• W2100090684 hasConcept C71924100 @default.
• W2100090684 hasConceptScore W2100090684C121608353 @default.
• W2100090684 hasConceptScore W2100090684C126322002 @default.
• W2100090684 hasConceptScore W2100090684C143998085 @default.
• W2100090684 hasConceptScore W2100090684C2777008409 @default.
• W2100090684 hasConceptScore W2100090684C2777899217 @default.
• W2100090684 hasConceptScore W2100090684C2779159551 @default.
• W2100090684 hasConceptScore W2100090684C2779466945 @default.
• W2100090684 hasConceptScore W2100090684C2780192828 @default.
• W2100090684 hasConceptScore W2100090684C2780221984 @default.
• W2100090684 hasConceptScore W2100090684C38180746 @default.
• W2100090684 hasConceptScore W2100090684C71924100 @default.
• W2100090684 hasFunder F4320308982 @default.
• W2100090684 hasFunder F4320337337 @default.
• W2100090684 hasIssue "4" @default.
• W2100090684 hasLocation W21000906841 @default.
• W2100090684 hasLocation W21000906842 @default.
• W2100090684 hasLocation W21000906843 @default.
• W2100090684 hasLocation W21000906844 @default.
• W2100090684 hasOpenAccess W2100090684 @default.
• W2100090684 hasPrimaryLocation W21000906841 @default.
• W2100090684 hasRelatedWork W1978567513 @default.
• W2100090684 hasRelatedWork W2099235231 @default.

• next